APA

Charatcharoenwitthaya P., Wongpaitoon V., Komolmit P., Sukeepaisarnjaroen W., Tangkijvanich P., Piratvisuth T., Sanpajit T., Sutthivana C., Bunchorntavakul C., Sobhonslidsuk A., Chonprasertsuk S., Siripipattanamongkol C., Sethasine S. & Tanwandee T. (20201211). Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study. : BMC gastroenterology.

Chicago

Charatcharoenwitthaya Phunchai, Wongpaitoon Virasak, Komolmit Piyawat, Sukeepaisarnjaroen Wattana, Tangkijvanich Pisit, Piratvisuth Teerha, Sanpajit Theeranun, Sutthivana Chinnavat, Bunchorntavakul Chalermrat, Sobhonslidsuk Abhasnee, Chonprasertsuk Soonthorn, Siripipattanamongkol Chotipong, Sethasine Supatsri and Tanwandee Tawesak. 20201211. Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study. : BMC gastroenterology.

Harvard

Charatcharoenwitthaya P., Wongpaitoon V., Komolmit P., Sukeepaisarnjaroen W., Tangkijvanich P., Piratvisuth T., Sanpajit T., Sutthivana C., Bunchorntavakul C., Sobhonslidsuk A., Chonprasertsuk S., Siripipattanamongkol C., Sethasine S. and Tanwandee T. (20201211). Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study. : BMC gastroenterology.

MLA

Charatcharoenwitthaya Phunchai, Wongpaitoon Virasak, Komolmit Piyawat, Sukeepaisarnjaroen Wattana, Tangkijvanich Pisit, Piratvisuth Teerha, Sanpajit Theeranun, Sutthivana Chinnavat, Bunchorntavakul Chalermrat, Sobhonslidsuk Abhasnee, Chonprasertsuk Soonthorn, Siripipattanamongkol Chotipong, Sethasine Supatsri and Tanwandee Tawesak. Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study. : BMC gastroenterology. 20201211.